Ubs Group Ag My Md Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.22 - $0.58 $830 - $2,188	-3,774 Reduced 60.31%	2,484 $0
Q3 2023 Nov 09, 2023	BUY	$0.47 - $1.87 $2,941 - $11,702	6,258 New	6,258 $3,000
Q4 2022 Feb 08, 2023	BUY	$0.92 - $96.0 $6,727 - $701,952	7,312 New	7,312 $8,000
Q2 2022 Aug 10, 2022	BUY	$2.0 - $4.78 $2,154 - $5,148	1,077 New	1,077 $2,000
Q1 2022 May 16, 2022	SELL	$3.34 - $6.05 $5,931 - $10,744	-1,776 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$5.46 - $9.69 $12,465 - $22,122	-2,283 Reduced 56.25%	1,776 $11,000
Q3 2021 Nov 15, 2021	BUY	$4.64 - $7.94 $515 - $881	111 Added 2.81%	4,059 $29,000
Q2 2021 Aug 13, 2021	BUY	$3.39 - $6.98 $13,383 - $27,557	3,948 New	3,948 $25,000

30.2K

Ticker MYMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,470,000
Market Cap $67.5M
Description
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and o...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.